Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib combinations with radiotherapy and/or temozolomide in glioblastoma
NL-OMON48745Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pamiparib in glioblastoma (GBM) (4 arms), sponsored by BeiGene. Primary endpoints: Dose-limiting toxicities, Adverse events and 3 more. Started Jan 2019; status: completed.
02
Drugs
pamiparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON48745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48745.